Highlights Biocure Technology Inc.

Equities

CURE

CA09075T1075

Delayed Canadian Securities Exchange Other stock markets 07:00:00 11/09/2023 pm IST			5-day change	1st Jan Change
0.015 ^CAD	-25.00%		-.--%	-.--%

21/05	Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	22/05	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/05	CI
Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11	CI
Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc..	18/23/18	CI
Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25	CI
Sang Mok Lee acquired 46% of stake in BiocurePharm Corporation from Biocure Technology Inc..	31/23/31	CI
Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	29/23/29	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Sang Mok Lee agreed to acquire 46% of stake in BiocurePharm Corporation from Biocure Technology Inc. for CAD 0.27 million.	19/22/19	CI
Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/22/25	CI
Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	24/22/24	CI
Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/22/25	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI
Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	30/21/30	CI
Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia and Solid Tumor Cancers and Intent to Apply for Patents	30/21/30	CI
Biocure Technology Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	30/21/30	CI
Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	27/21/27	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	30/21/30	CI
Biocure Technology Corp. Enters into MOU with Symbasis GmbH	04/21/04	CI
BiocurePharm, Korea Announces the Submission of IND Application for Phase 1 Trial of CD19 CAR-T Therapy	30/20/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Biocure Technology Inc.

Equities

CURE

CA09075T1075

Highlights

Filters